Last reviewed · How we verify
NCT04937088: OLA COVID
Outpatient Liquid Aspirin (OLA)
Phase 2 trial testing ASA in Covid19 in 200 participants. Status unknown.
5 December 2022
Quick facts
| Lead sponsor | Louisiana State University Health Sciences Center in New Orleans |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 200 |
| Start date | 6 December 2021 |
| Primary completion | 5 December 2022 |
| Estimated completion | 5 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- ASA — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Louisiana State University Health Sciences Center in New Orleans
Who can join
40 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to obtain reliable and interpretable data to inform future trials regarding our hypothesis that a novel, liquid aspirin formulation can mitigate COVID -19 associated coagulopathy (CAC) . The potential impact is to reduce COVID-19 related hospitalization within 30 days of diagnosis due to (1) pulmonary events including respiratory failure; (2) cardiac events including myocardial infarction and myocarditis (3) venous or arterial thrombotic events; (4) acute renal insufficiency or failure.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
The roles of lipids in SARS-CoV-2 viral replication and the host immune response.
Theken KN, Tang SY, Sengupta S, FitzGerald GA. · · 2021 · cited 59× · PMID 34599996 · DOI 10.1016/j.jlr.2021.100129 -
Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection.
Chen P, Wu M, He Y, Jiang B, et al · · 2023 · cited 50× · PMID 37286535 · DOI 10.1038/s41392-023-01510-8 -
Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials.
Zong X, Wang X, Liu Y, Li Z, et al · · 2022 · cited 16× · PMID 36160149 · DOI 10.3389/fmed.2022.965790 -
Antiplatelet agents for the treatment of adults with COVID-19.
Fischer AL, Messer S, Riera R, Martimbianco ALC, et al · · 2023 · cited 5× · PMID 37489818 · DOI 10.1002/14651858.cd015078 -
Lipid metabolism, viral infection, and antiviral immunity: a new host-pathogen interface.
Yang LJ, Tang M, Yang L. · · 2026 · PMID 41868152 · DOI 10.3389/fcimb.2026.1765502
Verify or expand the search:
- PubMed search for NCT04937088
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ASA
Trials testing the same drug.
- NCT07468448 — Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe · Phase 3 · not yet recruiting
- NCT05625334 — Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-e · Phase 1 · completed
- NCT05122455 — Effects of Edoxaban on Platelet Aggregation · Phase 2, PHASE3 · completed
- NCT04229264 — Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients. · Phase 3 · unknown
- NCT03428373 — Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma · Phase 2, PHASE3 · unknown
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Louisiana State University Health Sciences Center in New Orleans trials
Trials by the same sponsor.
- NCT07462767 — Precision Microbiota Interventions for Senoreduction Trial · Phase 1, PHASE2 · not yet recruiting
- NCT07488156 — Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder · NA · not yet recruiting
- NCT07280260 — Clinical Performance of Nobel N1 System · Phase 4 · recruiting
- NCT06773715 — Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain · NA · recruiting
- NCT06874244 — Clinical Evaluation of no Needle Dental Anesthesia Compared to Syringe Anesthesia Delivery · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04937088 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Louisiana State University Health Sciences Center in New Orleans
- Last refreshed: 3 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04937088.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing